Author

F. Khani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Organism:mouse· 2

Frequent Co-Authors

A. Sboner· 3 shared B. D. Robinson· 3 shared C. E. Barbieri· 2 shared D. Liu· 2 shared E. Davicioni· 2 shared K. Lin· 2 shared L. D. Deonarine· 2 shared M. A. Augello· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Sboner

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Canonical AREs are tumor suppressive regulatory elements in the prostate

M. A. Augello, X. Chen, D. Liu, K. Lin, A. Hakansson, M. Sjostrom, F. Khani, L. D. Deonarine, Y. Liu, J. Travascio-Green, J. Wu, M. Loda, F. Y. Feng, B. D. Robinson, E. Davicioni, , C. Barbieri

This study identifies canonical AREs as tumor suppressive regulatory elements in prostate cancer, showing their reactivation can induce death in AR+ cancer cells and is linked to better prognosis.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

Distinct mesenchymal cell states mediate prostate cancer progression

H. Pakula, M. Omar, R. Carelli, F. Pederzoli, G. N. Fanelli, T. Pannellini, L. Van Emmenis, S. Rodrigues, C. Fidalgo-Ribeiro, P. V. Nuzzo, N. J. Brady, M. Jere, C. Unkenholz, M. K. Alexanderani, F. Khani, , M. Loda

This study identifies distinct mesenchymal cell states in prostate cancer stroma that correlate with metastatic progression and develops a gene signature to predict patient outcomes.

bioRxiv · Mar 29, 2023Cancer Biology

The evolution of genomic, transcriptomic, and single-cell protein markers of metastatic upper tract urothelial carcinoma

K. Ohara, A. F. Rendeiro, B. Bhinder, K. W. Eng, H. Ravichandran, D. Pisapia, A. Vosoughi, E. Fernandez, K. Shohdy, J. Manohar, S. Beg, D. Wilkes, B. Robinson, F. Khani, R. Bareja, , J. M. Mosquera

The paper examines genomic, transcriptomic, and single-cell protein markers in metastatic upper tract urothelial carcinoma, finding discordant genomic alterations but stable molecular and immune subtypes between primary and metastatic tumors.

bioRxiv · Nov 16, 2021 · PreprintCancer Biology

SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape

I. Grbesa, M. A. Augello, D. Liu, D. R. McNally, C. D. Gaffney, D. Huang, K. Lin, R. Goueli, B. D. Robinson, F. Khani, L. D. Deonarine, M. Blattner, O. Elemento, E. Davicioni, A. Sboner, C. E. Barbieri

This study shows that SPOP mutations in prostate cancer alter the chromatin landscape and AR-driven transcription, making tumors more responsive to AR-targeted therapies.

bioRxiv · Apr 20, 2021 · PreprintCancer Biology